Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Get your Portfolio automatically emailed to you up to 4 times a day with Barchart Premier. FREE 30 Day Trial
Stocks | Futures | Watchlist | News | More
or
Faster, Cleaner, Better.

Krystal Biotech Inc (KRYS)

Krystal Biotech Inc (KRYS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 7,094,358
  • Shares Outstanding, K 28,998
  • Annual Sales, $ 290,520 K
  • Annual Income, $ 89,160 K
  • EBIT $ 158 M
  • EBITDA $ 165 M
  • 60-Month Beta 0.48
  • Price/Sales 24.63
  • Price/Cash Flow 53.22
  • Price/Book 6.29

Options Overview Details

View History
  • Implied Volatility 36.54% (-1.26%)
  • Historical Volatility 25.55%
  • IV Percentile 2%
  • IV Rank 3.34%
  • IV High 73.25% on 04/08/25
  • IV Low 35.27% on 12/05/25
  • Expected Move (DTE 3) 9.69 (3.99%)
  • Put/Call Vol Ratio 0.00
  • Today's Volume 1,062
  • Volume Avg (30-Day) 222
  • Put/Call OI Ratio 2.24
  • Today's Open Interest 8,162
  • Open Int (30-Day) 9,560
  • Expected Range 233.29 to 252.67

Analyst Rating / Earnings Estimates

Current Rating
See More
Strong Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/25
See More
  • Average Estimate 1.62
  • Number of Estimates 3
  • High Estimate 1.92
  • Low Estimate 1.40
  • Prior Year 1.52
  • Growth Rate Est. (year over year) +6.58%

Price Performance

See More
Period Period Low Period High Performance
1-Month
202.99 +19.70%
on 11/18/25
248.60 -2.26%
on 12/12/25
+36.82 (+17.86%)
since 11/14/25
3-Month
151.88 +59.98%
on 09/16/25
248.60 -2.26%
on 12/12/25
+87.27 (+56.05%)
since 09/15/25
52-Week
122.80 +97.87%
on 05/23/25
248.60 -2.26%
on 12/12/25
+79.34 (+48.48%)
since 12/13/24

Most Recent Stories

More News
Krystal Biotech to Present at 8th Annual Evercore Healthcare Conference

PITTSBURGH, Nov. 26, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the 8 th Annual Evercore Healthcare Conference...

KRYS : 242.98 (-0.68%)
Krystal Biotech Announces Third Quarter 2025 Financial and Operating Results

$97.8 million in 3Q VYJUVEK revenue and $623.2 million since U.S. launch VYJUVEK launched in Germany in 3Q; launched in France and Japan in 4Q Updated U.S. VYJUVEK label expands eligible...

KRYS : 242.98 (-0.68%)
Krystal Biotech to Report Third Quarter 2025 Financial Results on November 3, 2025

PITTSBURGH, Oct. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that it will report its third quarter 2025 financial results on Monday, November...

KRYS : 242.98 (-0.68%)
William Blair Remains a Buy on Krystal Biotech (KRYS)

William Blair analyst Sami Corwin maintained a Buy rating on Krystal Biotech today. The company’s shares opened today at $183.38.Elevate Your Investing Strategy: Take advantage of TipRanks Premium at...

KRYS : 242.98 (-0.68%)
Krystal Biotech Receives FDA Platform Technology Designation for HSV-1 Viral Vector Used in KB801 for the Treatment of Neurotrophic Keratitis

PITTSBURGH, Oct. 14, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the United States Food and Drug Administration (FDA) granted platform technology...

KRYS : 242.98 (-0.68%)
Krystal Biotech Announces FDA Approval of Updated VYJUVEK® Label

Revised label allows treatment of DEB patients from birth VYJUVEK can now be applied by patients and caregivers PITTSBURGH, Sept. 15, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc....

KRYS : 242.98 (-0.68%)
Krystal Biotech to Present at Cantor Global Healthcare Conference 2025

PITTSBURGH, Sept. 02, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc . (the “Company”) (NASDAQ: KRYS) today announced that the Company will participate in the Cantor Global Healthcare Conference...

KRYS : 242.98 (-0.68%)
Krystal Biotech Announces Update on Development Plans for Oncology Program KB707 and Prioritization of Inhaled KB707 for the Treatment of Non-Small Cell Lung Cancer

PITTSBURGH, Aug. 21, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced an update on development plans for...

KRYS : 242.98 (-0.68%)
Krystal Biotech Announces Second Quarter 2025 Financial and Operating Results

$96.0 million in 2Q VYJUVEK revenue and $525.4 million since launch in 3Q 2023 VYJUVEK approved in Japan for the treatment of DEB patients from birth Strong balance sheet, ending the...

KRYS : 242.98 (-0.68%)
Krystal Biotech to Report Second Quarter 2025 Financial Results on August 4, 2025

PITTSBURGH, July 29, 2025 (GLOBE NEWSWIRE) -- Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS), a commercial-stage biotechnology company, today announced that it will report its second quarter...

KRYS : 242.98 (-0.68%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 100% Buy with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

Relative Strength just crossed below 80%. The market has dropped from extreme overbought territory, indicating a possible trend reversal.

See More Share

Business Summary

Krystal Biotech, Inc. is a gene therapy company. It engaged in developing and commercializing novel treatments for patients suffering from dermatological diseases. Krystal Biotech, Inc. is based in Pittsburgh, United States.

See More

Key Turning Points

3rd Resistance Point 253.67
2nd Resistance Point 250.54
1st Resistance Point 246.76
Last Price 242.98
1st Support Level 239.84
2nd Support Level 236.71
3rd Support Level 232.93

See More

52-Week High 248.60
Last Price 242.98
Fibonacci 61.8% 200.54
Fibonacci 50% 185.70
Fibonacci 38.2% 170.85
52-Week Low 122.80

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar